课题基金 / 基金详情

LIPIN 1 IN THE REGULATION OF HEPATIC LIPID METABOLISM

LIPIN 1 IN THE REGULATION OF HEPATIC LIPID METABOLISM
LIPIN 1 对肝脏脂质代谢的调节
批准号:
8996163
负责人:
Brian N Finck
金额:
$33.06万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-01-01 至 2018-01-31

项目摘要

项目成果

Brian N Finck的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):大量证据表明肥胖与几种慢性疾病的风险增加有关,包括非酒精性脂肪性肝病(NAFLD)。NAFLD包括单纯性肝脂肪变性和更严重的非酒精性脂肪性肝炎(NASH;与脂肪变性病变相关的肝脏炎症和纤维化)。随着肥胖在美国的流行,NAFLD的发病率也在迅速上升,成为肝脏疾病最常见的病因。虽然脂肪性肝炎可发展为肝硬化和肝功能衰竭,但NAFLD最常见的合并症是肝脏胰岛素抵抗和循环葡萄糖、脂质和炎症介质浓度的全身异常。需要全面了解影响NAFLD发生和发展的因素。最近的研究表明,脂蛋白家族(脂蛋白1、2和3)通过其双功能分子活动协调并连接肝脏线粒体和甘油脂代谢。脂素是在内质网膜上使磷脂酸(PA)去磷酸化形成二酰基甘油(DAG) (PAP活性)的代谢酶,但也在细胞核中通过与dna结合的转录因子相互作用来调节编码线粒体酶的基因表达。我们偶然建立了一个小鼠模型,使我们能够区分肝脏中脂素1的两种分子功能。本文提出的研究旨在:[1]表征和区分肝细胞中脂素1的核胞质作用,[2]确定脂素2是否也具有转录调节功能并确定其靶点的基因组图谱,[3]确定在PAP活性降低的情况下促进肝甘油三酯合成的代偿机制。这些研究结果不仅将对我们对脂质蛋白生物学的理解产生影响,而且将为中间代谢的基本分子调控提供新的见解。
英文摘要
DESCRIPTION (provided by applicant): Overwhelming evidence links obesity with increased risk for several chronic diseases including non- alcoholic fatty liver disease (NAFLD). The condition, NAFLD, encompasses both simple hepatic steatosis and the more severe non-alcoholic steatohepatitis (NASH; hepatic inflammation and fibrosis associated with steatotic lesions). With the epidemic of obesity in the U.S., the occurrence of NAFLD has risen exuberantly, becoming the most common cause of liver disease. Although steatohepatitis can progress to cirrhosis and liver failure, the most common co-morbidity of NAFLD is hepatic insulin resistance and systemic abnormalities in circulating glucose, lipid, and inflammatory mediator concentrations. A complete understanding of the factors that influence the development and progression of NAFLD is needed. Recent work has suggested that the lipin family of proteins (lipin 1, 2, and 3) coordinate and connect hepatic mitochondrial and glycerolipid metabolism through their bifunctional molecular activities. Lipins are metabolic enzymes that dephosphorylate phosphatidic acid (PA) to form diacylglycerol (DAG) (PAP activity) at the endoplasmic reticulum membrane, but also act in the nucleus to regulate the expression of genes encoding mitochondrial enzymes by interacting with DNA-bound transcription factors. We have serendipitously generated a mouse model that will allow us to distinguish the two molecular functions of lipin 1 in liver. The studies proposed herein are designed to: [1] characterize and distinguish the nucleocytoplasmic effects of lipin 1 in hepatocytes, [2] to determine whether lipin 2 also has transcriptional regulatory function and define the genomic profile of its targets, and [3] to define the compensatory mechanisms facilitating hepatic triglyceride synthesis in the context of diminished PAP activity. The results f these studies will not only have implications for our understanding of the biology of lipin proteins, but will also provide new insight into the basic molecular regulation of intermediary metabolism.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
A sweet new role for ubiquitin-specific protease 2 in controlling hepatic gluconeogenesis.
泛素特异性蛋白酶 2 在控制肝糖异生中发挥着甜蜜的新作用。
DOI: 10.2337/db12-0198
发表时间: 2012
期刊: Diabetes
影响因子: 7.7
作者: [Finck,BrianN]
通讯作者: Finck,BrianN
Phenomaster NG Mouse Metabolic Phenotyping System
  • 批准号:
    10427654
  • 项目类别:
  • 资助金额:
    $52.37万
  • 财政年份:
    2022
  • 负责人:
    Brian N Finck
  • 依托单位:
Novel insulin-sensitizing NASH/diabetes drugs.
  • 批准号:
    10218153
  • 项目类别:
  • 资助金额:
    $49.75万
  • 财政年份:
    2019
  • 负责人:
    Brian N Finck
  • 依托单位:
Novel insulin-sensitizing NASH/diabetes drugs.
  • 批准号:
    10096091
  • 项目类别:
  • 资助金额:
    $49.75万
  • 财政年份:
    2019
  • 负责人:
    Brian N Finck
  • 依托单位:
Novel insulin-sensitizing NASH/diabetes drugs.
  • 批准号:
    10471836
  • 项目类别:
  • 资助金额:
    $49.75万
  • 财政年份:
    2019
  • 负责人:
    Brian N Finck
  • 依托单位:
海外基金